FindTrial
Sign In

Metastatic renal cell carcinoma (mRCC) patients treated with sunitinib as first-line therapy.

Clinical and prognostic implications of delta-like ligand 4 and hypoxia-inducible factors in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib as first-line therapy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13004016
Enrollment
Unknown
Registered
2013-07-24
Start date
2008-12-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic renal cell carcinoma

Interventions

metastatic renal cell carcinoma patients:sunitinib or IFN-alpha

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) ps 0-2; (2) pathologically diagnosed as renal cell carcinoma; (3) haven't received any chemotherapy, target therapy or immunotherapy before this study.

Exclusion criteria

Exclusion criteria: (1) second primary tumor; (2) severe respiratory, renal or hepatic disfunction.

Design outcomes

Primary

MeasureTime frame
Progression-free survival (PFS) and Overall survival (OS);—

Countries

China

Contacts

Public ContactMian Xie

The First Affiliated Hospital of Guangzhou Medical University

mianxie@gird.cn+86 13622283335

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026